$CELU
Celularity Inc Stock $celu

$celu Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023011440 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$3.935M	$4.129M	$17.98M
YoY Change	-33.7%	-14.97%	-15.75%
Cost Of Revenue	$2.003M	$5.247M	$19.67M
YoY Change	-50.25%	12.6%	103.72%
Gross Profit	$1.932M	-$1.118M	-$1.690M
YoY Change	1.2%	-670.41%	-114.47%
Gross Profit Margin	49.1%	-27.08%	-9.4%
Selling, General & Admin	$13.93M	$19.08M	$66.02M
YoY Change	-15.35%	44.46%	-7.46%
% of Gross Profit	721.22%
Research & Development	$16.95M	$10.99M	$78.36M
YoY Change	-21.79%	-55.48%	-11.31%
% of Gross Profit	877.38%
Depreciation & Amortization	$2.363M	$2.439M	$9.436M
YoY Change	3.46%	-6.41%	7.02%
% of Gross Profit	122.31%
Operating Expenses	$30.89M	-$22.21M	$144.4M
YoY Change	-19.01%	-246.65%	-9.59%
Operating Profit	-$63.87M	$21.10M	-$25.60M
YoY Change	53.48%	-241.09%	-76.53%
Interest Expense	-$161.0K	$210.0K	$365.0K
YoY Change	-2783.33%	-127.96%	-112.86%
% of Operating Profit		1.0%
Other Income/Expense, Net	-$147.0K	$6.752M	$39.81M
YoY Change	-99.31%	-42.2%	344.2%
Pretax Income	-$64.02M	$24.45M	$14.21M
YoY Change	1.83%	-708.13%	-114.19%
Income Tax	$0.00	$13.00K	$13.00K
% Of Pretax Income		0.05%	0.09%
Net Earnings	-$64.02M	$24.43M	$14.19M
YoY Change	1.83%	-704.8%	-114.18%
Net Earnings / Revenue	-1626.86%	591.77%	78.95%
Basic Earnings Per Share	-$0.41		$0.10
Diluted Earnings Per Share	-$0.41	$0.13	$0.09
COMMON SHARES
Basic Shares Outstanding	165.0M	145.0M	139.9M
Diluted Shares Outstanding	155.4M		149.8M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.532M	$13.97M	$14.00M
YoY Change	-82.24%	-62.5%	-62.41%
Cash & Equivalents	$8.532M	$13.97M	$14.00M
Short-Term Investments
Other Short-Term Assets	$5.823M	$7.262M	$7.200M
YoY Change	-16.47%	363000.0%	1.72%
Inventory	$5.484M	$5.308M	$5.300M
Prepaid Expenses
Receivables	$5.165M	$6.966M	$8.800M
Other Receivables	$0.00	$0.00	-$1.800M
Total Short-Term Assets	$25.00M	$33.50M	$33.50M
YoY Change	-66.99%	-43.31%	-43.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$74.06M	$75.66M	$88.70M
YoY Change	-5.01%	-16.52%	-2.12%
Goodwill	$90.06M	$119.7M
YoY Change	-26.96%	-2.93%
Intangibles	$120.5M	$121.0M
YoY Change	-1.79%	-1.78%
Long-Term Investments
YoY Change
Other Assets	$352.0K	$376.0K	$38.20M
YoY Change	-98.13%	5.92%	113.26%
Total Long-Term Assets	$337.4M	$367.6M	$367.6M
YoY Change	-5.87%	3.53%	3.54%
TOTAL ASSETS
Total Short-Term Assets	$25.00M	$33.50M	$33.50M
Total Long-Term Assets	$337.4M	$367.6M	$367.6M
Total Assets	$362.4M	$401.1M	$401.1M
YoY Change	-16.53%	-3.15%	-3.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.755M	$5.810M	$5.800M
YoY Change	-15.96%	-37.64%	-37.75%
Accrued Expenses	$24.56M	$16.40M	$13.80M
YoY Change	82.76%	40.66%	88.01%
Deferred Revenue	$2.199M	$2.273M
YoY Change		3.51%
Short-Term Debt	$30.95M	$37.60M	$37.60M
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$66.46M	$62.09M	$62.10M
YoY Change	155.27%	136.75%	136.8%
LONG-TERM LIABILITIES
Long-Term Debt	$4.745M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$318.0K	$321.0K	$140.1M
YoY Change	-99.9%	-4.18%	-46.2%
Total Long-Term Liabilities	$318.0K	$321.0K	$140.1M
YoY Change	-99.9%	-4.18%	-51.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$66.46M	$62.09M	$62.10M
Total Long-Term Liabilities	$318.0K	$321.0K	$140.1M
Total Liabilities	$206.8M	$202.2M	$202.2M
YoY Change	-39.94%	-35.76%	-35.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$709.5M	-$645.5M
YoY Change	-1.8%	-2.74%
Common Stock	$17.00K	$15.00K
YoY Change	21.43%	25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$155.6M	$198.9M	$198.9M
YoY Change
Total Liabilities & Shareholders Equity	$362.4M	$401.1M	$401.1M
YoY Change	-16.53%	-3.15%	-3.15%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$64.02M	$24.43M	$14.19M
YoY Change	1.83%	-704.8%	-114.18%
Depreciation, Depletion And Amortization	$2.363M	$2.439M	$9.436M
YoY Change	3.46%	-6.41%	7.02%
Cash From Operating Activities	-$15.00M	-$29.59M	-$137.9M
YoY Change	-56.22%	-7.68%	25.23%
INVESTING ACTIVITIES
Capital Expenditures	$209.0K	$779.0K	$5.236M
YoY Change	-85.63%	-133.83%	-15.59%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$3.209M	-$779.0K	-$5.236M
YoY Change	120.7%	-66.17%	-11.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.76M	1.685M	119.8M
YoY Change	-72.56%	-266.17%	21.59%
NET CHANGE
Cash From Operating Activities	-15.00M	-29.59M	-137.9M
Cash From Investing Activities	-3.209M	-779.0K	-5.236M
Cash From Financing Activities	12.76M	1.685M	119.8M
Net Change In Cash	-5.445M	-28.68M	-23.27M
YoY Change	-150.47%	-18.9%	33.47%
FREE CASH FLOW
Cash From Operating Activities	-$15.00M	-$29.59M	-$137.9M
Capital Expenditures	$209.0K	$779.0K	$5.236M
Free Cash Flow	-$15.20M	-$30.36M	-$143.1M
YoY Change	-57.42%	2.09%	23.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001752828
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38914
CY2022	dei	Entity Registrant Name EntityRegistrantName	Celularity Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1702591
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	170 Park Ave
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Florham Park
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07932
CY2022	dei	City Area Code CityAreaCode	(908)
CY2022	dei	Local Phone Number LocalPhoneNumber	768-2170
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	227400000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	165028879
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	Morristown, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13966000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37240000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1789000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	283000
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	4452000
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2745000
CY2022Q4	celu	Promissory Notes Receivable PromissoryNotesReceivable	2514000
CY2021Q4	celu	Promissory Notes Receivable PromissoryNotesReceivable	2488000
CY2022Q4	us-gaap	Inventory Net InventoryNet	5308000
CY2021Q4	us-gaap	Inventory Net InventoryNet	9549000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7262000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7078000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	33502000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	59100000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75655000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90625000
CY2022Q4	us-gaap	Goodwill Goodwill	119694000
CY2021Q4	us-gaap	Goodwill Goodwill	123304000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120994000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	123187000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13060000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14836000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14836000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	22949000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2721000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	376000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	355000
CY2022Q4	us-gaap	Assets Assets	401066000
CY2021Q4	us-gaap	Assets Assets	414128000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5810000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9317000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16402000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11661000
CY2021Q4	celu	Financing Obligations Current FinancingObligationsCurrent	3051000
CY2022Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	37603000
CY2022Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	37000000
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	37603000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2273000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2196000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62088000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26225000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2219000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1871000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	105945000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	232222000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27985000
CY2021Q4	celu	Financing Obligations Noncurrent FinancingObligationsNoncurrent	28085000
CY2022Q4	celu	Warrant Liability WarrantLiability	3598000
CY2021Q4	celu	Warrant Liability WarrantLiability	25962000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	9000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	321000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	335000
CY2022Q4	us-gaap	Liabilities Liabilities	202165000
CY2021Q4	us-gaap	Liabilities Liabilities	314710000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148921187
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148921187
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124307884
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124307884
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	12000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	844373000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	763087000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-645496000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-663681000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	198901000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	99418000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	401066000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414128000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17975000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21335000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78363000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88353000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	66021000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71341000
CY2022	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	-126277000
CY2021	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	-41145000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3610000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2193000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2192000
CY2022	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	43575000
CY2021	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	130394000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25600000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-109059000
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	365000
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	332000
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3171000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-42109000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13482000
CY2022	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	2522000
CY2022	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-147000
CY2021	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-1682000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	39805000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8961000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14205000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-100098000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	14192000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100118000
CY2022	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	9000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14201000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-100118000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139907029
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67057278
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	149830016
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67057278
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-531400000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	197000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	40010000
CY2021	celu	Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Additional Paid In Capital RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital	485598000
CY2021	celu	Reclassified From Warrant Liability To Additional Paid In Capital ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital	96398000
CY2021	us-gaap	Profit Loss ProfitLoss	-100118000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	99418000
CY2022	celu	Stock Issued During Period Value Reclassification Of Previously Exercised Stock Options StockIssuedDuringPeriodValueReclassificationOfPreviouslyExercisedStockOptions	441000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	948000
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-86000
CY2022	celu	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	46491000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4088000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	132000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15856000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6021000
CY2022	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent	20000
CY2022	us-gaap	Profit Loss ProfitLoss	14192000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	198901000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	14192000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100118000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9436000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8817000
CY2022	celu	Non Cash Lease Expense NonCashLeaseExpense	-59000
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1000
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1353000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1877000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	298000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-42109000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13482000
CY2022	celu	Inventory Reserve For Obsolescence InventoryReserveForObsolescence	904000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3610000
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	15856000
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	40010000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-126277000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-41145000
CY2022	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	2522000
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	5333000
CY2022	celu	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	186000
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	37000
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-2627000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3584000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1909000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16891000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6422000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-49000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3068000
CY2021	celu	Sale Of Net Operating Losses And Research And Development Tax Credits SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits	1356000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2948000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3007000
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	4710000
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1801000
CY2022	celu	Increase Decrease In Right Of Use Assets And Lease Liabilities IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities	263000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	425000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8382000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-137876000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-110096000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5236000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6203000
CY2021	celu	Proceeds From Promissory Note ProceedsFromPromissoryNote	300000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5236000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5903000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	46491000
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	39200000
CY2022	celu	Proceeds From The Sale Of Common Stock In Atm Offering ProceedsFromTheSaleOfCommonStockInAtmOffering	6519000
CY2022	celu	Payments Of At The Market Offering Costs And Commissions PaymentsOfAtTheMarketOfferingCostsAndCommissions	498000
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5000000
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000
CY2021	celu	Cash Received On Recapitalization CashReceivedOnRecapitalization	5386000
CY2021	celu	Proceeds From Investment ProceedsFromInvestment	20000000
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	30000000
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	83400000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	862000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	638000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	132000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2604000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	10862000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119838000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	98562000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23274000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17437000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52076000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69513000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28802000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52076000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	146000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	683000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	970000
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	4099000
CY2021	celu	Recapitalization From Merger RecapitalizationFromMerger	550113000
CY2021	celu	Cancellation Of Treasury Stock CancellationOfTreasuryStock	256000
CY2021	celu	Non Cash Assets Acquired From Merger NonCashAssetsAcquiredFromMerger	163000
CY2021	celu	Warrant Liability Assumed From Merger WarrantLiabilityAssumedFromMerger	59202000
CY2021	celu	Issuance Of Common Stock As Payment For Related Costs IssuanceOfCommonStockAsPaymentForRelatedCosts	10795000
CY2021	celu	Reclassification Of Warrant Liabilities To Equity ReclassificationOfWarrantLiabilitiesToEquity	96398000
CY2021	celu	Reclass Of Offering Costs Paid In Prior Year ReclassOfOfferingCostsPaidInPriorYear	153000
CY2022	celu	Reclassification Of Option Liabilities To Equity ReclassificationOfOptionLiabilitiesToEquity	441000
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-08-24
CY2022Q4	celu	Number Of Clinical Trials NumberOfClinicalTrials	3
CY2022	celu	Area Of Building AreaOfBuilding	147215
CY2018Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	0
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25600000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-137876000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-645496000
CY2022Q4	celu	Unrestricted Cash And Cash Equivalents UnrestrictedCashAndCashEquivalents	8600000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible impairment assessment, the valuation of inventory, contingent consideration, short-term debt, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14836000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14836000
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2020Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2021	celu	Reduction Of Research And Development Expense Resulting From Grant ReductionOfResearchAndDevelopmentExpenseResultingFromGrant	0
CY2022	celu	Reduction Of Research And Development Expense Resulting From Grant ReductionOfResearchAndDevelopmentExpenseResultingFromGrant	0
CY2022	celu	Payment Plans For Customer To Pay Over Time Period PaymentPlansForCustomerToPayOverTimePeriod	P24M
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	163000
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	252000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	celu	Instrument Specific Credit Risk Income InstrumentSpecificCreditRiskIncome	20000
CY2022	celu	Accumulated Other Comprehensive Income To Other Income Upon Short Term Debt Conversion AccumulatedOtherComprehensiveIncomeToOtherIncomeUponShortTermDebtConversion	11000
CY2022	celu	Minimum Percentage Of Recognized Tax Benefit Likelihood Of Being Realized Upon Ultimate Settlement With Tax Authority MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority	0.50
CY2022	celu	Income Loss IncomeLoss	14192000
CY2021	celu	Income Loss IncomeLoss	-100118000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139907029
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67057278
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9586018
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	336969
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	149830016
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67057278
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	53425649
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	69694763
CY2022	celu	Number Of Business Segments NumberOfBusinessSegments	3
CY2021	celu	Number Of Business Segments NumberOfBusinessSegments	3
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Customers</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of December 31, 2022, one of the Company's customers (Customer A) comprised </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company's outstanding gross accounts receivable, and two other customers comprised </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the outstanding gross accounts receivable. As of December 31, 2021, Customer A comprised of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company's outstanding gross accounts receivable, and one other customer comprised </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">of the outstanding</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">gross </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">accounts receivable. During the year ended December 31, 2022, the Company had two customers provide for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenue and Customer A provided for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenue. During the year ended December 31, 2021, the Company had one customer provide for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenue and Customer A provided for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In November 2017, the FDA provided guidance that established an updated framework for regulation of Human Cell & Tissue Products (“HCT/P”). The Company’s Interfyl products meet the criteria for minimal manipulation and homologous use as outlined within the applicable guidance and has an official designation from the FDA as an HCT/P product. As a result, the Company did not stop selling its Interfyl products when the FDA ended its enforcement discretion on May 31, 2021. However, the Center for Medicare and Medicaid Services (“CMS”) began rejecting claims for Interfyl submitted by Customer A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. The Company believes that CMS is not distinguishing the Interfyl products from its competitors’ products. While the Company and Customer A continue to work with CMS to resolve the rejected claims, a reserve of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,762</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> was recorded on Customer A’s accounts receivable balance as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Certain prior period amounts have been reclassified to conform with current year presentation.</span></p>
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:a.each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (the “Class A Common Stock” or “Common Stock”) equal to the Exchange Ratio (as defined below) (the “Per Share Merger Consideration”);b.each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, “Legacy Celularity Capital Stock”) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;c.each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;d.each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Class A Common Stock (and not Celularity Capital Stock) (each, a “Converted Warrant”) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the “Celularity Warrant Shares”) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); ande.each option to purchase Legacy Celularity Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a “Legacy Celularity Option”) was assumed by GX and converted into an option to purchase shares of Class A Common Stock (each, a “Converted Option”).
CY2021Q3	celu	Business Acquisition Transaction Costs Proceeds Net BusinessAcquisitionTransactionCostsProceedsNet	108786000
CY2021Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	21658000
CY2022	celu	Subscription Agreements Description SubscriptionAgreementsDescription	On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc., Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the “Subscribers”) purchased from Celularity an aggregate of 8,340,000 shares of Class A Common Stock (the “July 2021 PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the “Subscription Agreements”). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the July 2021 PIPE Shares.
CY2022Q4	celu	Convertible Note Receivable ConvertibleNoteReceivable	2514000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14688000
CY2022Q4	celu	Contingent Stock Consideration ContingentStockConsideration	186000
CY2022Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	37603000
CY2022Q4	celu	Warrant Liability Private Investment In Public Equity Warrants WarrantLiabilityPrivateInvestmentInPublicEquityWarrants	1402000
CY2022Q4	celu	Warrant Liability Sponsor Warrants WarrantLiabilitySponsorWarrants	1190000
CY2022Q4	celu	Warrant Liability Public Warrants WarrantLiabilityPublicWarrants	1006000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	147332000
CY2021Q4	celu	Convertible Note Receivable ConvertibleNoteReceivable	2488000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	39188000
CY2021Q4	celu	Warrant Liability Sponsor Warrants WarrantLiabilitySponsorWarrants	13600000
CY2021Q4	celu	Warrant Liability Public Warrants WarrantLiabilityPublicWarrants	12362000
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	258184000
CY2022	celu	Fair Value Assets Level One To Level Two Transfers Amount During Period FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod	0
CY2021	celu	Fair Value Assets Level One To Level Two Transfers Amount During Period FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod	0
CY2021	celu	Fair Value Assets Level Two To Level One Transfers Amount During Period FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod	0
CY2022	celu	Fair Value Assets Level Two To Level One Transfers Amount During Period FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022Q4	celu	Warrant Liability WarrantLiability	3598000
CY2021Q4	celu	Warrant Liability WarrantLiability	25962000
CY2020Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	76640000
CY2021	celu	Gain Loss Recognized In Earnings From Change In Fair Values GainLossRecognizedInEarningsFromChangeInFairValues	13482000
CY2021	celu	Reclassification Of Legacy Celularity Warrants To Equity ReclassificationOfLegacyCelularityWarrantsToEquity	-96398000
CY2021Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	25962000
CY2021Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	25962000
CY2022	celu	Private Investment In Public Equity Warrant Issuance PrivateInvestmentInPublicEquityWarrantIssuance	19745000
CY2022	celu	Gain Loss Recognized In Earnings From Change In Fair Values GainLossRecognizedInEarningsFromChangeInFairValues	42109000
CY2022Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	3598000
CY2022Q4	celu	Face Value Of Notes Receivable FaceValueOfNotesReceivable	4000000
CY2021Q4	celu	Face Value Of Notes Receivable FaceValueOfNotesReceivable	4000000
CY2022Q4	celu	Valuation Model That Relate To Sanuwave Common Stock ValuationModelThatRelateToSanuwaveCommonStock	0.02
CY2021Q4	celu	Valuation Model That Relate To Sanuwave Common Stock ValuationModelThatRelateToSanuwaveCommonStock	0.17
CY2022	celu	Scheduleofyorkvilleshort Termdebtvaluationmodel Tabletextblock ScheduleofyorkvilleshortTermdebtvaluationmodelTabletextblock	<p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Significant inputs for the Yorkville short-term debt valuation model are as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.854%;"/> <td style="width:1.944%;"/> <td style="width:1.0%;"/> <td style="width:16.203%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Common share price</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.29</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Credit spread</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13.71</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Dividend yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Term (years)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.71</span></span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.75</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Volatility</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">45.0</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Discount yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18.46</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2022Q4	celu	Valuation Input For Short Term Debt Share Price ValuationInputForShortTermDebtSharePrice	1.29
CY2022Q4	celu	Valuation Input For Short Term Debt Credit Spread ValuationInputForShortTermDebtCreditSpread	0.1371
CY2022Q4	celu	Valuation Input For Short Term Debt Dividend Yield ValuationInputForShortTermDebtDividendYield	0
CY2022	celu	Valuation Input For Short Term Debt Term ValuationInputForShortTermDebtTerm	P0Y8M15D
CY2022Q4	celu	Valuation Input For Short Term Debt Discount Yield ValuationInputForShortTermDebtDiscountYield	0.1846
CY2022Q4	celu	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	7719000
CY2021Q4	celu	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	2359000
CY2022Q4	celu	Inventory Work In Progress Current And Noncurrent InventoryWorkInProgressCurrentAndNoncurrent	12381000
CY2021Q4	celu	Inventory Work In Progress Current And Noncurrent InventoryWorkInProgressCurrentAndNoncurrent	5902000
CY2022Q4	celu	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	9256000
CY2021Q4	celu	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	4057000
CY2022Q4	celu	Inventory Gross Current And Noncurrent InventoryGrossCurrentAndNoncurrent	29356000
CY2021Q4	celu	Inventory Gross Current And Noncurrent InventoryGrossCurrentAndNoncurrent	12318000
CY2022Q4	celu	Inventory Reserve Current And Noncurrent InventoryReserveCurrentAndNoncurrent	1099000
CY2021Q4	celu	Inventory Reserve Current And Noncurrent InventoryReserveCurrentAndNoncurrent	48000
CY2022Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	28257000
CY2021Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	12270000
CY2022Q4	us-gaap	Inventory Net InventoryNet	5308000
CY2021Q4	us-gaap	Inventory Net InventoryNet	9549000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	22949000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2721000
CY2022Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	28257000
CY2021Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	12270000
CY2022Q4	celu	Prepaid Clinical Expense PrepaidClinicalExpense	5836000
CY2021Q4	celu	Prepaid Clinical Expense PrepaidClinicalExpense	3269000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	377000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1493000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1356000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1258000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1399000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1049000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2410000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7262000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7078000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95986000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	105404000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20331000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14779000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75655000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90625000
CY2021Q4	us-gaap	Sale Leaseback Transaction Accumulated Depreciation SaleLeasebackTransactionAccumulatedDepreciation	5971000
CY2022	us-gaap	Depreciation Depreciation	7243000
CY2021	us-gaap	Depreciation Depreciation	6625000
CY2021Q4	us-gaap	Goodwill Goodwill	123304000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3610000
CY2022Q4	us-gaap	Goodwill Goodwill	119694000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23993000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23993000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11499000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9306000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12494000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14687000
CY2022	celu	Indefinite Lived Intangible Assets Amortization Method IndefiniteLivedIntangibleAssetsAmortizationMethod	indefinite
CY2021	celu	Indefinite Lived Intangible Assets Amortization Method IndefiniteLivedIntangibleAssetsAmortizationMethod	indefinite
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120994000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	123187000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2193000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2192000
CY2022Q4	celu	Accrued Clinical Trial Expense AccruedClinicalTrialExpense	2659000
CY2021Q4	celu	Accrued Clinical Trial Expense AccruedClinicalTrialExpense	1861000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	880000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1653000
CY2022Q4	celu	Accrued Research And Development Software AccruedResearchAndDevelopmentSoftware	7333000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2576000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2193000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1753000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3038000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1598000
CY2022	us-gaap	Lease Cost LeaseCost	4636000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	126000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3824000
CY2022Q4	celu	Accruals For Construction In Progress AccrualsForConstructionInProgress	322000
CY2021Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	2000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2632000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4321000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16402000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11661000
CY2022	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	3803000
CY2021	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	1132000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90625000
CY2021Q4	celu	Current Portion Of Financing Obligation CurrentPortionOfFinancingObligation	3051000
CY2021Q4	celu	Operating Lease Financing Obligations Noncurrent OperatingLeaseFinancingObligationsNoncurrent	28085000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-663681000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2834000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2895000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2969000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3042000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3116000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3190000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	70341000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	85553000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	57568000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	27985000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P23Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1112
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	common stock are entitled to one vote per share
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	Preferred Stock were entitled to vote
CY2022	us-gaap	Preferred Stock Dividend Payment Terms PreferredStockDividendPaymentTerms	The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of 6% of the Original Issue Price per year; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date, no cash dividends were declared or paid.
CY2022	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.06
CY2022	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	13281386
CY2022Q1	us-gaap	Shares Issued SharesIssued	13281386
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15856000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40010000
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	33458360
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.027
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.771
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.804
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.43
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.13
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7997000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2959000
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	131256
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	23508000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M25D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	269007
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.83
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2613217
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	10.21
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13723000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7186000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	567000
CY2021	celu	Expense Related To Performance Awards ExpenseRelatedToPerformanceAwards	31000
CY2021	celu	Award Modification Expense AwardModificationExpense	121000
CY2021	celu	Unrecognized Expense Related To Performance Awards UnrecognizedExpenseRelatedToPerformanceAwards	0
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17975000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21335000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4067000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12449000
CY2022	celu	Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue	5004000
CY2021	celu	Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue	4928000
CY2022	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	4579000
CY2021	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	13310000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4492000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4067000
CY2022	celu	Incentive Payment IncentivePayment	0
CY2020Q2	celu	Reimbursement Of Cost Under License Agreement ReimbursementOfCostUnderLicenseAgreement	75000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1159000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	989000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	13000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	17000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.389
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.098
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.015
CY2022	celu	Effective Income Tax Rate Reconciliation Interest Accretion Expense EffectiveIncomeTaxRateReconciliationInterestAccretionExpense	-1.869
CY2021	celu	Effective Income Tax Rate Reconciliation Interest Accretion Expense EffectiveIncomeTaxRateReconciliationInterestAccretionExpense	0.086
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.691
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.461
CY2022	celu	Effective Income Tax Rate Reconciliation Mark To Market Warrant EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant	-0.585
CY2021	celu	Effective Income Tax Rate Reconciliation Mark To Market Warrant EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant	0.028
CY2022	celu	Effective Income Tax Rate Reconciliation Deferred True Up EffectiveIncomeTaxRateReconciliationDeferredTrueUp	0.002
CY2021	celu	Effective Income Tax Rate Reconciliation Deferred True Up EffectiveIncomeTaxRateReconciliationDeferredTrueUp	0.017
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.082
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.053
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.031
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.002
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	102723000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	88327000
CY2022Q4	celu	Deferred Tax Assets Tax Credit Carryforwards Research And Development DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment	5674000
CY2021Q4	celu	Deferred Tax Assets Tax Credit Carryforwards Research And Development DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment	7672000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14321000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11748000
CY2022Q4	celu	Deferred Tax Assets Startup Costs DeferredTaxAssetsStartupCosts	588000
CY2021Q4	celu	Deferred Tax Assets Startup Costs DeferredTaxAssetsStartupCosts	697000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3905000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4471000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1135000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1103000
CY2022Q4	celu	Deferred Tax Assets Unicap DeferredTaxAssetsUnicap	6000
CY2021Q4	celu	Deferred Tax Assets Unicap DeferredTaxAssetsUnicap	6000
CY2022Q4	celu	Deferred Tax Assets Imputed Interest On Contingent Payments DeferredTaxAssetsImputedInterestOnContingentPayments	5654000
CY2021Q4	celu	Deferred Tax Assets Imputed Interest On Contingent Payments DeferredTaxAssetsImputedInterestOnContingentPayments	4410000
CY2022Q4	celu	Deferred Tax Assets Legal Fee Capitalization And Amortization DeferredTaxAssetsLegalFeeCapitalizationAndAmortization	1342000
CY2021Q4	celu	Deferred Tax Assets Legal Fee Capitalization And Amortization DeferredTaxAssetsLegalFeeCapitalizationAndAmortization	1550000
CY2022Q4	celu	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	19318000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3121000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1535000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	157787000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	121519000
CY2022Q4	celu	Deferred Tax Liabilities In Process Research And Development DeferredTaxLiabilitiesInProcessResearchAndDevelopment	27271000
CY2021Q4	celu	Deferred Tax Liabilities In Process Research And Development DeferredTaxLiabilitiesInProcessResearchAndDevelopment	29232000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	27271000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	29232000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	130525000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92297000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	10000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1028000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	242000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1270000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	242000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1028000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1028000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1270000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	celu	Net Operating Losses And Unused Research And Development Tax Credits Sold NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold	1356000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2022Q4	us-gaap	Assets Assets	401066000
CY2021Q4	us-gaap	Assets Assets	414128000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17975000
CY2022	us-gaap	Gross Profit GrossProfit	-1690000
CY2022	us-gaap	Direct Operating Costs DirectOperatingCosts	144198000
CY2022	celu	Segment Contribution SegmentContribution	-145888000
CY2022	celu	Indirect Expenses IndirectExpenses	-120288000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25600000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21335000
CY2021	us-gaap	Gross Profit GrossProfit	11682000
CY2021	us-gaap	Direct Operating Costs DirectOperatingCosts	159694000
CY2021	celu	Segment Contribution SegmentContribution	-148012000
CY2021	celu	Indirect Expenses IndirectExpenses	-38953000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-109059000
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000

Files In Submission

Name	View Source	Status
0000950170-23-011440-index-headers.html	Edgar Link	pending
0000950170-23-011440-index.html	Edgar Link	pending
0000950170-23-011440.txt	Edgar Link	pending
0000950170-23-011440-xbrl.zip	Edgar Link	pending
celu-20221231.htm	Edgar Link	pending
celu-20221231.xsd	Edgar Link	pending
celu-ex10_14.htm	Edgar Link	pending
celu-ex23_1.htm	Edgar Link	pending
celu-ex31_1.htm	Edgar Link	pending
celu-ex31_2.htm	Edgar Link	pending
celu-ex32_1.htm	Edgar Link	pending
celu-ex99_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img153432159_0.jpg	Edgar Link	pending
img153432159_1.jpg	Edgar Link	pending
img153432159_10.jpg	Edgar Link	pending
img153432159_11.jpg	Edgar Link	pending
img153432159_12.jpg	Edgar Link	pending
img153432159_13.jpg	Edgar Link	pending
img153432159_14.jpg	Edgar Link	pending
img153432159_15.jpg	Edgar Link	pending
img153432159_16.jpg	Edgar Link	pending
img153432159_2.jpg	Edgar Link	pending
img153432159_3.jpg	Edgar Link	pending
img153432159_4.jpg	Edgar Link	pending
img153432159_5.jpg	Edgar Link	pending
img153432159_6.jpg	Edgar Link	pending
img153432159_7.jpg	Edgar Link	pending
img153432159_8.jpg	Edgar Link	pending
img153432159_9.jpg	Edgar Link	pending
celu-20221231_lab.xml	Edgar Link	unprocessable
celu-20221231_cal.xml	Edgar Link	unprocessable
celu-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
celu-20221231_pre.xml	Edgar Link	unprocessable
celu-20221231_htm.xml	Edgar Link	completed
img173972250_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELU
Celularity Inc Stock $celu

2023 Q1 Form 10-K Financial Statement

#000095017023011440 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELU Celularity Inc Stock $celu

2023 Q1 Form 10-K Financial Statement

#000095017023011440 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELU
Celularity Inc Stock $celu